Washington Trust Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Washington Trust Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-38	Closed	-$1.66K	–	704
2023 Q3	$1.66K	Hold	38	–	–	﹤0.01%	650
2023 Q2	$1.37K	Hold	38	–	–	﹤0.01%	641
2023 Q1	$1.41K	Hold	38	–	–	﹤0.01%	749
2022 Q4	$1.72K	Hold	38	–	–	﹤0.01%	737
2022 Q3	$3K	Hold	38	–	–	﹤0.01%	834
2022 Q2	$3K	Hold	38	–	–	﹤0.01%	855
2022 Q1	$3K	Hold	38	–	–	﹤0.01%	923
2021 Q4	$6K	Buy	+38	New	+$5.9K	﹤0.01%	834

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Washington Trust Advisors's MRTX Position: Q4 2023 in Review

Washington Trust Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 38 shares — an estimated $1.66K sold.

Washington Trust Advisors first reported a position in MRTX in Q4 2021 and held it in 8 quarters. The position peaked at $6K in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Washington Trust Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Washington Trust Advisors sold 38 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.66K.
Washington Trust Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Washington Trust Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Washington Trust Advisors's 13F filing for Q4 2023, filed 18 Jan 2024.